Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company’s lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women’s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the company’s research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women’s and men’s health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson’s disease. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.

  • Neurocrine Biosciences to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
    on September 8, 2020 at 8:01 pm

    Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 18th Annual Global Healthcare Conference at 1:30 p.m. ET on Monday, September 14, 2020. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.

  • Neurocrine Biosciences to Present New Data from its Movement Disorder Programs for Tardive Dyskinesia and Parkinson's Disease at Upcoming Scientific Meetings
    on September 3, 2020 at 8:06 pm

    Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present new data as part of 30 abstracts accepted from its movement disorder programs for tardive dyskinesia and Parkinson's disease at the upcoming virtual scientific meetings, 2020 Psych Congress on September 10–13 and the MDS Virtual Congress 2020 on September 12–16.

  • Neurocrine Biosciences to Present at the Citi 15th Annual BioPharma Virtual Conference
    on September 2, 2020 at 8:01 pm

    Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Citi 15th Annual BioPharma Virtual Conference at 12:35 p.m. ET on Wednesday, September 9, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.

  • Looking Into Neurocrine Biosciences's Return On Capital Employed
    on August 28, 2020 at 2:11 pm

    Looking at Q2, Neurocrine Biosciences (NASDAQ: NBIX) earned $76.60 million, a 30.05% increase from the preceding quarter. Neurocrine Biosciences also posted a total of $302.40 million in sales, a 27.54% increase since Q1. In Q1, Neurocrine Biosciences earned $58.90 million, and total sales reached $237.10 million.Why ROCE Is Significant Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed in a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth in a company and is a sign of higher earnings per share for shareholders in the future. A low or negative ROCE suggests the opposite. In Q2, Neurocrine Biosciences posted an ROCE of 0.09%.Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.View more earnings on NBIXReturn on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.For Neurocrine Biosciences, the return on capital employed ratio shows the number of assets can actually help the company achieve higher returns, an important note investors will take into account when gauging the payoff from long-term financing strategies.Q2 Earnings Insight Neurocrine Biosciences reported Q2 earnings per share at $1.42/share, which beat analyst predictions of $0.73/share.See more from Benzinga * Benzinga's Top Upgrades, Downgrades For August 4, 2020 * Earnings Scheduled For August 3, 2020 * Stocks That Hit 52-Week Highs On Thursday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Neurocrine Biosciences Inc (NBIX) Q2 2020 Earnings Call Transcript
    on August 4, 2020 at 1:30 pm

    NBIX earnings call for the period ending June 30, 2020.

  • How Is Neurocrine Biosciences' (NASDAQ:NBIX) CEO Paid Relative To Peers?
    on August 4, 2020 at 12:38 pm

    This article will reflect on the compensation paid to Kevin Gorman who has served as CEO of Neurocrine Biosciences...

  • How Neurocrine Biosciences Crushed It in Q2
    on August 4, 2020 at 10:34 am

    Neurocrine Biosciences' (NASDAQ: NBIX) 30% plunge earlier this year during the coronavirus-fueled market meltdown is practically all but forgotten now. Here's what you need to know about Neurocrine's impressive Q2 update. Neurocrine reported revenue of $302.4 million in the second quarter, a 65% increase from the $183.5 million reported in the prior-year period.

  • Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates
    on August 3, 2020 at 9:15 pm

    Neurocrine (NBIX) delivered earnings and revenue surprises of 24.62% and 18.28%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Neurocrine Biosciences Stock Pops After Earnings Double, Shatter Views
    on August 3, 2020 at 8:37 pm

    Late Monday, Neurocrine Biosciences reported second-quarter earnings that doubled the year-earlier figure, shattering analyst expectations and sending shares of NBIX stock higher after hours.

  • Neurocrine Biosciences Reports Second Quarter 2020 Financial Results
    on August 3, 2020 at 8:01 pm

    Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2020 and provided revised full-year 2020 financial expense guidance.

[custom-facebook-feed id=]

Get it free: FREE: Zoom Backgrounds Bundle https://stacksocial.com/sales/free-zoom-backgrounds-bundle?rid=5921417 via @StackSocial

Check out my latest article: Buy-Side M&A Strategy: Financing an Acquisition https://www.linkedin.com/pulse/buy-side-ma-strategy-financing-acquisition-ian-shanno via @LinkedIn

Corporate: a professional approach to business
Finance: about the future
Consulting: tapping outside expertise for corporate finance excellence
https://alignmt.com

Check out my latest article: Investor Presentation Tips: 11 Steps to Writing an Effective Investor Deck https://www.linkedin.com/pulse/investor-presentation-tips-11-steps-writing-effective-ian-shanno via @LinkedIn

Load More...

Neurocrine Biosciences, Inc.

12780 El Camino Real
San Diego, CA 92130

+1 (858) 617-7600

www.neurocrine.com

September 2020
S M T W T F S
 12345
6789101112
13141516171819
20212223242526
27282930  

©2020 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account